<DOC>
	<DOCNO>NCT00996060</DOCNO>
	<brief_summary>1 . Primary Objective : The primary endpoint study document toxicity , reversibility toxicity , regimen hydralazine valproic acid patient advance , unresectable , previously treat lung cancer , acceptable standard therapy available . A primary endpoint determine potential dose limit toxicity , Maximal Tolerated Dose regimen . 2 . Secondary Objectives : The secondary endpoint study determine potential anti-tumor effect , determine objective tumor response ( complete partial response ) , clinical benefit ( complete partial response , clinical benefit ) , time tumor response , time tumor progression , overall survival .</brief_summary>
	<brief_title>Use Hydralazine Valproic Acid Advanced Solid Tumor Malignancies</brief_title>
	<detailed_description>This study open-label , non-randomized , dose-escalation phase I trial enroll sequential cohort .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>1 . All patient lung cancer disease previously treat and/or acceptable standard treatment regimen available , treat definitively either surgery radiotherapy . 2 . All appropriate candidate treatment , candidate treatment protocols high priority . 3 . All patient ECOG/Zubrod/SWOG performance status le 2 time initiation therapy 4 . Adequate endorgan function 5 . No severe comorbid disease 6 . Ability provide inform consent . 7 . Signed Informed Consent 8 . ECOG/Zubrod/SWOG Performance Status less 2 9 . Life expectancy great 8 week 10 . Male female ' age great 18 year 11 . Patients childbearing potential must use effective mean contraception . 12 . Histologic diagnosis lung cancer advance treat adequately radiotherapy surgery ; metastatic disease , standard chemotherapeutic option remain available 13 . All participant must either previously receive refused standard chemotherapy 14 . Baseline laboratory value ( bone marrow , renal , hepatic ) : Adequate bone marrow function : 1 . Absolute neutrophil count great 1000/µL 2 . Platelet count great 100'000/µL Renal function : a. Serum creatinine le 2.0 mg % Hepatic function : 1 . Bilirubin le 1.5x normal 2 . Serum calcium le 12 mg/dl Exclusion Criteria 1 . Pregnant lactating female 2 . Myocardial infarction ischemia within 6 month Cycle 0 ' Day 0 3 . Uncontrolled ' clinically significant dysrhythmia 4 . Prior radiotherapy indicator lesion unless objective evidence tumor growth lesion 5 . Prior autoimmune disease 6 . Uncontrolled metastatic disease central nervous system 7 . Radiotherapy within 2 week Cycle 1 ' Day 14 8 . Surgery within 2 week Cycle 1 ' Day 14 9 . Any co morbid condition ' view attend physician ' render patient high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Advanced Lung Cancer</keyword>
	<keyword>Unresectable Lung cancer</keyword>
	<keyword>Previously treat lung cancer</keyword>
</DOC>